<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HC0428B88779044C085A7DA1AFAD1DB4F" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 5343 IH: Ensuring Patient Access to Critical Breakthrough Products Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-09-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5343</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250915">September 15, 2025</action-date><action-desc><sponsor name-id="M001213">Mr. Moore of Utah</sponsor> (for himself, <cosponsor name-id="D000617">Ms. DelBene</cosponsor>, <cosponsor name-id="Y000067">Mr. Yakym</cosponsor>, <cosponsor name-id="S001185">Ms. Sewell</cosponsor>, <cosponsor name-id="B001257">Mr. Bilirakis</cosponsor>, and <cosponsor name-id="T000482">Mrs. Trahan</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to ensure prompt coverage of breakthrough devices under the Medicare program.</official-title></form><legis-body id="H06DE127FE3D246BF8D57BADF4040B573" style="OLC"> 
<section id="HA07CCDD3F33D4FAFBF5075E07FBFCB9A" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Ensuring Patient Access to Critical Breakthrough Products Act</short-title></quote>.</text></section> 
<section id="HCBAAD21133254C96A8CFC41F2761E992" section-type="subsequent-section"><enum>2.</enum><header>Ensuring prompt coverage of breakthrough devices under the Medicare program</header> 
<subsection id="H8A4B6F77C27D47B3B743E430631A0B33"><enum>(a)</enum><header>Ensuring coverage through a transitional coverage period</header> 
<paragraph id="H350FF652DF0A4151A2D8A122BD73896A"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1862(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y(a)(1)</external-xref>) is amended—</text> <subparagraph id="HBBE40FF3391F4AC8B02E9B29AE426462"><enum>(A)</enum><text>in subparagraph (O), by striking <quote>and</quote> at the end;</text></subparagraph> 
<subparagraph id="HC78323DB69EA40468DE9D152F0684049"><enum>(B)</enum><text>in subparagraph (P), by adding <quote>and</quote> at the end; and</text></subparagraph> <subparagraph id="HFF57821C05114FFABFD5E5A3274D3C40"><enum>(C)</enum><text>by inserting after subparagraph (P) the following new subparagraph:</text> 
<quoted-block style="OLC" id="HC852C8C62DC5454782925BF2089CEE63" display-inline="no-display-inline"> 
<subparagraph id="HA25D86B05D6A42ACB6CD3E0E62969146" indent="up1"><enum>(Q)</enum><text display-inline="yes-display-inline">in the case of a breakthrough device (as defined in section 1861(nnn)) furnished during the transitional coverage period (as so defined) with respect to such device, which is not furnished for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member in accordance with the Food and Drug Administration-approved labeling for such device and for the indication for which such device was provided priority review under section 515B of the Federal Food, Drug, and Cosmetic Act, or that the Secretary finds, based on a review of clinical data, presents an undue risk of harm that outweighs the potential clinical benefits for individuals entitled to benefits under part A or enrolled under part B;</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph> <paragraph id="H60FF97902A9E4A9591326AC5D5D4FD74"><enum>(2)</enum><header>Definitions</header><text display-inline="yes-display-inline">Section 1861 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x</external-xref>) is amended by adding at the end the following new subsection:</text> 
<quoted-block style="OLC" id="H439BB5D7BFCA422E89CCC3ED63AD08DB" display-inline="no-display-inline"> 
<subsection id="H256F9FA2572840E09D1B34F0341A2836"><enum>(nnn)</enum><header>Breakthrough device</header> 
<paragraph id="H4D45A5D420B84D44ADECBF4C50D2CDAC"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The term <quote>breakthrough device</quote> means a device that—</text> <subparagraph id="H49C2611FAB084023ACA729F8F577F6BF"><enum>(A)</enum><text>is so designated by the Secretary under section 1899D; and</text></subparagraph> 
<subparagraph id="HE7C0EEF56A154FD0BC1EE7B62C97A037"><enum>(B)</enum><text display-inline="yes-display-inline">is furnished at such frequency as specified in the Food and Drug Administration-approved labeling for such device (or, in the case such device has no frequency so specified, at such frequency as determined appropriate by the Secretary).</text></subparagraph></paragraph> <paragraph id="H8449C15D3188444B929E1E92838D0011"><enum>(2)</enum><header>Transitional coverage period</header><text>The term <quote>transitional coverage period</quote> means, with respect to a breakthrough device, the 4-year period that begins on the date that such device is so designated by the Secretary under section 1899D.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph> 
<paragraph id="HE83C339DF7C6478CBE1336F175B1F55A"><enum>(3)</enum><header>Breakthrough device determinations</header><text>Part E of title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x et seq.</external-xref>) is amended by adding at the end the following new section:</text> <quoted-block style="OLC" id="H7602C7EA6FEC4F6B8E39755B3CEE063E" display-inline="no-display-inline"> <section id="HAE6C5520F55E4F358FD05391C9BA3E54"><enum>1899D.</enum><header>Designation of breakthrough devices</header> <subsection id="H792B9E5E487B4BB0A570D9155BDE8DE7"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Beginning 18 months after the date of the enactment of this section, upon application of a manufacturer of a device (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act) that is cleared, classified, or approved under section 510(k), 513(f)(2), or 515 of such Act on or after the date of the enactment of this section, the Secretary shall designate such device as a breakthrough device if the Secretary determines that such device meets the criteria specified in subsection (b).</text></subsection> 
<subsection id="H5221911218AF48C79897E952F9B9D54E"><enum>(b)</enum><header>Criteria</header><text>For purposes of subsection (a), the criteria specified in this subsection are, with respect to a device, the following:</text> <paragraph id="H10B14D70AB9748C9BA55404BCBB9ADE4"><enum>(1)</enum><text>The device is provided with priority review pursuant to section 515B of the Federal Food, Drug, and Cosmetic Act.</text></paragraph> 
<paragraph id="H82EC8D2B83A74BBB820635EAD6CD59C1" commented="no"><enum>(2)</enum><text>In the case such device is cleared under section 510(k) of such Act, such device is so cleared based on clinical data, which may include clinical trial information from an applicable device clinical trial (as such terms are defined in section 402(j) of such Act), that included individuals entitled to benefits under part A or enrolled under part B.</text></paragraph> <paragraph id="HC4414B6F55FB4A5E9BC6F6DEBD04D165"><enum>(3)</enum><text>The device would, without application of section 1862(a), otherwise be covered under part A or B.</text></paragraph> 
<paragraph id="H4DE660D1BE924B9298D88B3CBEA01A37" commented="no"><enum>(4)</enum><text>The device does not, based on a review of clinical data, present an undue risk of harm that outweighs the potential clinical benefits for individuals entitled to benefits under part A or enrolled under part B, as determined by the Secretary.</text></paragraph></subsection> <subsection id="H417363DB79C24A75A6D7A306D721DF8E"><enum>(c)</enum><header>Determination process</header> <paragraph id="H74F6162595DA46B98FB235E387689D89"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall make a determination with respect to the designation of a device that is the subject of an application described in subsection (a) not later than 6 months after such application is submitted to the Secretary.</text></paragraph> 
<paragraph id="H13075798C0744C6598E507C42CB41CE9"><enum>(2)</enum><header>Explanation required in case of nondesignation</header><text>With respect to a device that is the subject of an application described in subsection (a), in the case that the Secretary determines that such device does not meet the criteria specified in subsection (b), the Secretary shall notify the manufacturer of such device of such determination and include in such notification an identification of the specific criterion or criteria that such device failed to meet and an explanation of why such device failed to meet such criterion or criteria.</text> </paragraph></subsection> <subsection id="H27948BCBFF3E4A5F832ECBDC8973F5A8"><enum>(d)</enum><header>Reports</header><text>The Secretary shall submit to Congress on an annual basis a report specifying—</text> 
<paragraph id="H198D66B938924314A303CA7BD7FB19B3"><enum>(1)</enum><text>the number of applications received under this section during such year;</text></paragraph> <paragraph id="H45FE7A1DC32846078FAEA76A929C3B44"><enum>(2)</enum><text>the number of devices designated as breakthrough devices under this section during such year; and</text></paragraph> 
<paragraph id="H3607A932CD0544A480FF0B9D0D82964D"><enum>(3)</enum><text display-inline="yes-display-inline">the number of applications for a designation for a device under this section with respect to which the Secretary determined that such device did not meet the criteria specified in subsection (b) during such year.</text></paragraph></subsection> <subsection id="H1DF43E48B4F849F9A2A89A6F6E753E76"><enum>(e)</enum><header>Review of aberrant billing</header><text>The Secretary may conduct a review of the medical necessity and reasonableness of a breakthrough device furnished by a provider of service or supplier that the Secretary determines has an aberrant billing pattern with respect to such a device or otherwise is an outlier with respect to the furnishing of such device compared to similarly situated providers of services and suppliers.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection> 
<subsection id="HC6D0D1055E934353A557BF6DDCDE6DB9" commented="no"><enum>(b)</enum><header>Ensuring issuance of national coverage determination during transition period</header><text display-inline="yes-display-inline">Section 1862(l)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y(l)(2)</external-xref>) is amended by adding at the end the following new flush sentence:</text> <quoted-block style="OLC" id="H35964611E78A47F3BB29EE212FF57593" display-inline="no-display-inline"> <quoted-block-continuation-text quoted-block-continuation-text-level="paragraph">In the case of a request for a national coverage determination with respect to a breakthrough device (as defined in section 1861(nnn)), the Secretary shall ensure that a final decision is made on such request (or determine that such device is otherwise covered under this title) prior to the end of the transitional coverage period (as so defined) for such device if such request was submitted to the Secretary before the date that is 9 months (or 12 months, in the case such request is a request to which subparagraph (B) applies) before the last day of such period.</quoted-block-continuation-text><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="H948A5B400A374B7882C27EB674AED5A6"><enum>(c)</enum><header>Funding</header><text display-inline="yes-display-inline">In addition to amounts otherwise available, there are appropriated to the Centers for Medicare &amp; Medicaid Services Program Management Account, out of any monies in the Treasury not otherwise appropriated, $10,000,000 for each of fiscal years 2025 through 2030, to remain available until expended, to carry out the amendments made by this section.</text></subsection></section> 
</legis-body></bill>

